RECEIVED


AUG 0 1 2001

TÉCH CENTER 1600/2900

SEQUENCE LISTING

```
<110> Imperial Cancer Research Technology Limited
<120> Polypeptides and their use in therapy
<130> IMPW/P18999PC
<140>
<141>
<160> 2
<170> PatentIn Ver. 2.0
<210> 1
<211> 49
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: double stranded
      oligonucl/eotide
<400> 1
cacagtcagg acatcatcat catcatcatt aaggatcctc tagaggtac
                                                                49
<210>
```

```
<211> 728
<212> PRT
<213> h. sapiens
<400> 2
Met Trp Val Thr Lys Leu Leu Pro Ala Leu Leu Gln His Val Leu
                  5
                                     10
                                                         15
Leu His Leu Leu Leu Pro Ile Ala Ile Pro Tyr Ala Glu Gly Gln
                                 25
             20
                                                     30
Arg Lys Arg Arg Asn Thr Ile His Glu Phe Lys Lys Ser Ala Lys Thr
                             40
                                                 45
         35
Thr Leu Ile Lys Ile Asp Pro Ala Leu Lys L/e Lys Thr Lys Lys Val
     50
                         55
                                             60
Asn Thr Ala Asp Gln Cys Ala Asn Arg Cys Thr Arg Asn Lys Gly Leu
                     70
                                         75
                                                             80
 65
Pro Phe Thr Cys Lys Ala Phe Val Phe Asp Lys Ala Arg Lys Gln Cys
                                     90
                                                         95
                85
Leu Trp Phe Pro Phe Asn Ser Met Ser Ser Gly Val Lys Lys Glu Phe
            100
                                105
                                                    110
Gly His Glu/Phe Asp Leu Tyr Glu Asn Lys Asp Tyr Ile Arg Asn Cys
                            120
                                                125
```



B3

Thr Leu Asp Pro His Thr Arg Trp Glu Tyr Cys Ala Ile Lys Thr Cys Ala Asp Asn Thr Met Asn Asp Thr Asp Val Pro Leu Glu Thr Thr 1/91u Cys Ile Gln Gly Gln Gly Glu Gly Tyr Arg Gly Thr Val Asn Thr Ile Trp Asn Gly Ile Pro Cys Gln Arg Trp Asp Ser Gl/n Tyr Pro His Glu His Asp Met Thr Pro Glu Asn Phe Lys Cys/Lys Asp Leu Arg Glu Asn Tyr Cys Arg Asn Pro Asp Gly Ser Glu Ser Pro Trp Cys Phe Thr Thr Asp Pro Asn Ile Arg Val Gl/ Tyr Cys Ser Gln Ile Pro Asn Cys Asp \Box Met Ser His Gly Gln Asp Cys Tyr Arg Gly Asn Gly Lys Asn Tyr Met Gly Asn Leu Ser Gln Thr Arg Ser Gly Leu Thr Cys Ser Met Trp Asp Lys Asm Met Glu Asp Leu His Arg His Ile Phe Trp Glu Pro Asp Ala

B3 Cont

Ser Lys Leu Asn Glu Asn Tyr Cys Arg Asn Pro Asp Asp Ala/His

Gly Pro Trp Cys Tyr Thr Gly Asn Pro Leu Ile Pro Trp Asp Tyr Cys

Pro Ile Ser Arg Cys Glu Gly Asp Thr Thr Pro Thr/Ile Val Asn Leu

Asp His Pro Val Ile Ser Cys Ala Lys Thr Lys Gln Leu Arg Val Val

Asn Gly Ile Pro Thr Arg Thr Asn Ile Gly Trp Met Val Ser Leu Arg **\$**05

Tyr Arg Asn Lys His Ile Cys/Gly Gly Ser Leu Ile Lys Glu Ser Trp

Val Leu Thr Ala Arg 🕅 n Cys Phe Pro Ser Arg Asp Leu Lys Asp Tyr

Glu Ala Trp Leu/Gly Ile His Asp Val His Gly Arg Gly Asp Glu Lys

 \Box

Cys Lys Gl/n Val Leu Asn Val Ser Gln Leu Val Tyr Gly Pro Glu Gly

 \Box

Ser Asp Leu Val Leu Met Lys Leu Ala Arg Pro Ala Val Leu Asp Asp Phe Val Ser Thr Ile Asp Leu Pro Asn Tyr Gly Cys Thr Ile Pro Glu Lys Thr Ser Cys Ser Val Tyr Gly Trp Gly Tyr Thr Gly Leu Ile Asn Tyr Asp Gly Leu Leu Arg Val Ala His Leu Tyr/Ile Met Gly Asn Glu Lys Cys Ser Gln His His Arg Gly Lys Val Thr Leu Asn Glu Ser Glu Ile Cys Ala Gly Ala Glu Lys Ile Gly Ser Gly Pro Cys Glu Gly Asp Tyr Gly Gly Pro Leu Val Cys Glu Gln His Lys Met Arg Met Val Leu Gly Val Ile Val Prø Gly Arg Gly Cys Ala Ile Pro Asn Arg Pro Gly Ile Phe Val Arg Val Ala Tyr Tyr Ala Lys Trp Ile His Lys Ile Ile

 β^3

	Leu	Thr	Tyr	Lys	Val	Pro	Gln	Ser
	0				725			
R3								
CINT	. 🗆							

ţ